4//SEC Filing
Folinsbee Thomas 4
Accession 0000899243-23-009251
CIK 0001839185other
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 6:21 AM ET
Size
7.4 KB
Accession
0000899243-23-009251
Insider Transaction Report
Form 4
Folinsbee Thomas
Director
Transactions
- Disposition to Issuer
Class B Ordinary Shares
2023-03-16−25,000→ 0 total→ Class A Ordinary Shares (25,000 underlying)
Footnotes (3)
- [F1]As described in the prospectus for the initial public offering (File No. 333-255722) of Summit Healthcare Acquisition Corp. ("SMIH") under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, automatically converted into Class A ordinary shares, par value $0.0001 per share, of SMIH at the time of the SMIH's initial business combination, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights.
- [F2]On March 16, 2023, pursuant to a Business Combination Agreement dated as of September 29, 2022 (the "Business Combination Agreement"), by and among SMIH, YishengBio Co., Ltd ("YS Biopharma"), Oceanview Bioscience Acquisition Co., Ltd., a direct wholly owned subsidiary of YS Biopharma ("Merger Sub I") and Hudson Biomedical Group Co., Ltd., a direct wholly owned subsidiary of YS Biopharma ("Merger Sub II"), (i) Merger Sub I merged with and into SMIH (the "First Merger"), with SMIH surviving the First Merger as the surviving entity (the "Surviving Entity") and remaining as a wholly-owned subsidiary of YS Biopharma and (ii) the Surviving Entity merged with and into Merger Sub II (the "Second Merger"), with Merger Sub II surviving the Second Merger as the surviving company (the "Surviving Company") and remaining as a wholly-owned subsidiary of YS Biopharma.
- [F3](Continued from Footnote 2) Immediately before the effective time of the First Merger, an aggregate of 1,446,525 Class B ordinary shares held by Summit Healthcare Acquisition Sponsor LLC, a Cayman Islands limited liability company (the "Sponsor") was surrendered for nil consideration, and after such surrender, each Class B ordinary share ceased to be outstanding and automatically converted into the right to receive one ordinary share of YS Biopharma.
Documents
Issuer
Summit Healthcare Acquisition Corp.
CIK 0001839185
Entity typeother
Related Parties
1- filerCIK 0001706382
Filing Metadata
- Form type
- 4
- Filed
- Mar 20, 8:00 PM ET
- Accepted
- Mar 21, 6:21 AM ET
- Size
- 7.4 KB